2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.07C.02 Perioperative Cadonilimab and Chemotherapy in Stage II-IIIA Non-Small-Cell Lung Cancer: Preliminary Results from a Phase II Study

EP.07C.02 Perioperative Cadonilimab and Chemotherapy in Stage II-IIIA Non-Small-Cell Lung Cancer: Preliminary Results from a Phase II Study

Back to course

Pdf Summary

This preliminary analysis from a Phase II study indicates that adding cadonilimab to neoadjuvant chemotherapy for patients with resectable stage II to IIIA non–small-cell lung cancer (NSCLC) shows a promising pathological response and has a well-tolerated safety profile. As the study is ongoing, extended follow-up is needed to accurately determine event-free survival. <br /><br />Cadonilimab, a first-in-class bispecific antibody that targets PD-1 and CTLA-4, is being tested to improve antitumor efficacy and safety in patients with early-stage NSCLC. The study, with a prospective, single-arm design, enrolled patients with stage II-IIIA resectable NSCLC and no prior systemic anticancer treatment. The primary endpoint is pathological complete response (pCR), while secondary endpoints include major pathological response (MPR), objective response rate (ORR), event-free survival (EFS), and safety.<br /><br />From the first eight patients analyzed, characteristics include a median age of 59, with 75% being male and a similar percentage having a smoking history. The majority had squamous histology and were at stage IIIA. A total of six patients underwent successful R0 resection, with four achieving MPR and two achieving pCR. No disease progression was observed pre-surgery, and seven patients exhibited an objective response.<br /><br />Safety data revealed no unexpected treatment-related toxic effects, primarily limited to grade 1 or 2 adverse events. Grade 3 adverse events included hypothyroidism, resulting in treatment cessation for one patient, and third-degree atrioventricular block, which led to surgical cancellation. No grade 4 events or deaths occurred, underscoring a manageable safety profile for cadonilimab.<br /><br />This study is funded by Akeso Biopharma Co Ltd, with ongoing patient enrollment to confirm these promising initial findings.

Asset Subtitle

Huijuan Wang

Meta Tag

Speaker Huijuan Wang

Topic Early-Stage Non-small Cell Lung Cancer

Keywords

cadonilimab

neoadjuvant chemotherapy

non-small-cell lung cancer

phase II study

pathological response

safety profile

bispecific antibody

PD-1 and CTLA-4

event-free survival

Akeso Biopharma